Datavault AI Inc. (NASDAQ: DVLT) has announced an expansion of its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS), extending the use of its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The expanded relationship aims to support patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions. This replaces the preferred shares originally contemplated for tax optimization purposes. The companies stated that the agreement accelerates the deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This move has significant implications for the healthcare industry, as it introduces blockchain-based solutions that give patients greater control over their health data. By enabling tokenization and monetization of real-world assets, individuals may be able to securely share their medical information with providers, researchers, or wellness platforms while retaining ownership and potentially earning compensation. The technology also supports AI-driven remote patient monitoring and IoT population health management, which could improve health outcomes and reduce costs.
Datavault AI is known for its AI-driven data experiences and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions through its Acoustic Sciences and Data Sciences divisions. The Acoustic Sciences division features patented technologies like WiSA, ADIO, and Sumerian for spatial and multichannel wireless high-definition sound transmission. The Data Science division leverages Web 3.0 and high-performance computing for experiential data perception, valuation, and secure monetization.
The expanded agreement positions Datavault AI to tap into the growing health and wellness market, which is seeing increased demand for patient-centered data solutions. The partnership with DataMEDS could lead to new business models where patients have a stake in how their data is used, potentially disrupting traditional healthcare data management. For investors, the deal provides Datavault AI with an equity stake in DataMEDS, aligning incentives for successful commercialization.
Datavault AI’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics, and marketing automation. The Information Data Exchange enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata. The company is headquartered in Philadelphia, PA, and more information is available at https://dvlt.ai.
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT.
